STAT
MAY 9, 2024
Twenty-seven years ago today, a 3-year-old boy in Hong Kong developed a sore throat, spiked a fever, and started to cough. Six days later, he was hospitalized; six days after that, he died of acute respiratory distress caused by viral pneumonia. Testing showed the toddler, who’d had contact with sick chickens before becoming ill, had been infected with H5N1 bird flu.
Drug Topics
MAY 9, 2024
Tandem Diabetes Care, Inc has reported 224 injuries associated with a software malfunction in a companion insulin app, leading the company to issue a recall of the technology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
MAY 9, 2024
A clinical pharmacist discusses his work in the mental health space while stressing the importance of advocating for and checking in with one another’s emotional well-being.
STAT
MAY 9, 2024
When it comes to federal agencies communicating to the public about H5N1 bird flu, it feels like a classic case of Yogi Berra’s déjà vu all over again. In the wake of pointed criticism about its failure to release new information about the growing H5N1 outbreak in livestock, the Animal and Plant Health Inspection Service of the U.S.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MAY 9, 2024
A UK report has said that inflation and geopolitical instability have led to a “dramatic drop” in investment in smaller companies developing new medicines, with a knock-on effect on the entire life sciences industry.
STAT
MAY 9, 2024
The intersection of the mental health crisis among young Americans and the growing burden of unpaid caregiving is generating an expanding, particularly vulnerable, and unacknowledged population: young people who act as caregivers for siblings with special health care needs, physically or mentally ill parents, ailing grandparents, or other loved ones.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
MAY 9, 2024
Weeks after the global public health community sounded the alarm on the shortage of cholera vaccine, the World Health Organization moved to prequalify a new cholera vaccine last month. The vaccine is a simplified version of the two existing oral vaccines, both produced by Korean vaccine manufacturer EuBiologics Co. The company will begin making the new vaccine, called Euvichol-S, this year.
Drug Topics
MAY 9, 2024
One of the biggest issues pharmacists are watching is the Medicare Part D redesign and copay smoothing policy.
STAT
MAY 9, 2024
A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough. Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.
Drug Topics
MAY 9, 2024
Since biosimilars first launched, unique pricing incentives and strategies have been created to incentives adoption.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
MAY 9, 2024
Google DeepMind and Isomorphic Labs' newly launched AlphaFold 3 extends the power of the AI model to 'all life’s molecules'
The Checkup by Singlecare
MAY 9, 2024
Amoxicillin , an antibiotic in the penicillin family, is commonly prescribed to treat a variety of bacterial infections, such as ear infections, pneumonia, strep throat, and urinary tract infections. It’s a broad-spectrum treatment that works by breaking down the walls that shield bacteria, neutralizing their ability to grow and spread, and allowing your immune system to clear infections.
Fierce Pharma
MAY 9, 2024
As argenx continues to scoop up biologics market share with its antibody fragment Vyvgart in generalized myasthenia gravis (gMG), the Dutch immunology outfit is confident that it’s “just at the beg | As argenx continues to scoop up biologics market share with its antibody fragment Vyvgart in generalized myasthenia gravis, the Dutch immunology outfit is confident that it’s “just at the beginning of the growth curve” in its inaugural indication.
Drug Topics
MAY 9, 2024
Test your knowledge of allergy and asthma clinical guidelines.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
MAY 9, 2024
After telegraphing more than a hundred potential layoffs in March in connection with plans to stop construction of a massive Seagen facility, Pfizer is plowing ahead with efforts to streamline its | Pfizer has proposed another round of staff reductions and role changes at legacy Seagen, this time hitting Seagen’s European headquarters in Switzerland, where 74 positions could be up for the chop.
STAT
MAY 9, 2024
What happens when a common virus jumps from birds to cows? And should we be concerned? This week on “The Readout LOUD,” STAT senior infectious diseases reporter Helen Branswell walks us through ongoing H5N1 outbreak in the U.S. and issues with monitoring the spread.
European Pharmaceutical Review
MAY 9, 2024
Withdrawal of the marketing authorisation for the COVID-19 vaccine (ChAdOx1-S [recombinant]) Vaxzevria (SRD) by the European Medicines Agency on 7 May, follows a request by AstraZeneca. “Global demand for all COVID vaccines is now much lower and overall supply exceeds demand. This is in marked contrast to the early part of the pandemic when supply was limited and distribution very limited, especially in poorer countries.
STAT
MAY 9, 2024
Even with the recent awareness that clinical trials often lack the diversity that would make them representative, women and people of color remain underrepresented in studies. The work of bringing diversity to research is complex, and several experts gathered at the Milken Institute Global Conference on Wednesday to discuss potential strategies to make progress, starting with ways to build trust among the communities that have a history of being mistreated or exploited by the scientific communit
Pharmaceutical Technology
MAY 9, 2024
Anixa Biosciences has expanded its partnership with Cleveland Clinic to develop additional vaccines for cancers.
STAT
MAY 9, 2024
Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue. That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.
Fierce Pharma
MAY 9, 2024
While Merck & Co.’s Keytruda already boasts a pair of approvals to treat certain forms of endometrial cancer, a recent effort to prove the PD-1 inhibitor’s worth as a post-surgery add-on therap | While Merck & Co.’s Keytruda already boasts a pair of approvals to treat certain forms of endometrial cancer, a recent effort to prove the PD-1 inhibitor’s worth as a post-surgery add-on therapy in newly diagnosed patients has fallen short.
STAT
MAY 9, 2024
BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world. These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later.
European Pharmaceutical Review
MAY 9, 2024
Regulatory agencies in the US across three sectors: agriculture and environmental, have produced a joint plan to “update, streamline, and clarify” regulations and oversight mechanisms for biotechnology products. The plan, developed by the US Environmental Protection Agency (EPA), the US Food and Drug Administration (FDA), and the US Department of Agriculture (USDA), helps to address US President Biden’s related goals, including and improving the “transparency, predictability, coordination, and
Pharmacy Times
MAY 9, 2024
This issue of Pharmacy Practice in Focus: Health Systems provides an overview of the considerations for the implementation of CRISPR and Cas9 cell-based gene therapies in sickle cell disease.
Fierce Pharma
MAY 9, 2024
In response to rapidly declining profits and the downfall of ADHD drug Vyvanse, Takeda is planning to throw 140 billion Japanese yen ($899 million) toward a company-wide restructuring campaign. | In a multi-year overhaul, the Japanese drugmaker plans to prioritize "organizational agility," procurement savings and tech efficiencies. It's all part of an effort to boost profit margins.
Pharmacy Times
MAY 9, 2024
This study is the first to preliminarily show that a community pharmacist intervention can produce a positive effect on reducing SABA reliance and improvement of ICS adherence in patients with asthma.
STAT
MAY 9, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congratulations on almost making it to the end of the week! For that, I have a little treat for you at the bottom of the newsletter.
Outsourcing Pharma
MAY 9, 2024
Neurocrine Biosciences Inc. has initiated its phase 1 clinical study, marking a significant stride in the evaluation of NBI-1117567, an investigational small molecule, oral compound developed by Nxera Pharma.
STAT
MAY 9, 2024
Rise and shine, everyone, another busy day is on the way. We can tell because countless birds are chirping outside our window, the pace of motor vehicles passing by our window is picking up, and the official mascots are busy foraging for snacks on the official grounds. As for us, we are engaged in the usual ritual of brewing cups of stimulation. Our choice today is orange cream.
Outsourcing Pharma
MAY 9, 2024
In today's fast-paced and demanding work environment, the importance of prioritizing employee mental health cannot be overstated.
pharmaphorum
MAY 9, 2024
A new metric developed by Phesi can predict the burden that clinical trials will impose on patients, allowing amendments that can improve the design, efficiency and cost
Pharmacy Times
MAY 9, 2024
Community-based pharmacists performed mightily at a cost-efficient scale and safety record that rivaled any in the history of health professions.
Fierce Pharma
MAY 9, 2024
Five months out from their twin FDA approvals in sickle cell disease (SCD), who’s winning the race to treat patients with their respective gene therapies—bluebird bio or partners Vertex Pharmaceuti | Five months out from their twin FDA approvals in sickle cell disease (SCD), who’s winning the race to treat patients with their respective gene therapies—bluebird bio or partners Vertex Pharmaceuticals and CRISPR Therapeutics?
Pharmacy Times
MAY 9, 2024
The results also showed that the PET scans could show damage to the individual’s brains, which was correlated with disability and fatigue.
Expert insights. Personalized for you.
145 
Let's personalize your content